We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+6.82%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$671M
AUM Growth
-$749M
Cap. Flow
-$596M
Cap. Flow %
-88.74%
Top 10 Hldgs %
41.79%
Holding
248
New
39
Increased
16
Reduced
53
Closed
62

Top Buys

Rank Stock Value
1
KZR
Kezar Life Sciences
KZR
+$11.5M
2
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$7.64M
3
CLDX icon
Celldex Therapeutics
CLDX
+$6.48M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$5.45M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$5.08M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$13.7M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$7.89M
3
CMPS
Compass Pathways
CMPS
+$6.85M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$5.93M
5
BCAB icon
BioAtla
BCAB
+$5.78M

Sector Composition

Rank Sector Weight
1 Healthcare 50.73%
2 Consumer Staples 0.3%
3 Technology 0.3%
4 Financials 0.11%
5 Real Estate 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STSA
51
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$2.83M 0.42%
629,384
– –
KZR
52
CALL
DELISTED
Kezar Life Sciences
KZR
$2.83M 0.42%
+16,930
New +$1.91M
AUTL
53
Autolus Therapeutics
AUTL
$397M
$2.83M 0.42%
544,819
– –
RCOR
54
DELISTED
Renovacor, Inc.
RCOR
$2.64M 0.39%
342,902
-100,000
-23% -$826K
RETA
55
PUT
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$2.64M 0.39%
100,000
-371,400
-79% -$28.7M
MGNX icon
56
MacroGenics
MGNX
$235M
$2.51M 0.37%
156,047
-32,431
-17% -$610K
VKTX icon
57
Viking Therapeutics
VKTX
$3.7B
$2.3M 0.34%
500,642
– –
OVID icon
58
Ovid Therapeutics
OVID
$414M
$2.26M 0.34%
705,082
-400,000
-36% -$1.37M
GOSS icon
59
CALL
Gossamer Bio
GOSS
$82.9M
$2.26M 0.34%
200,000
+14,600
+8% +$173K
ALLK
60
CALL
DELISTED
Allakos
ALLK
$2.13M 0.32%
218,000
+67,200
+45% +$5.51M
ARNA
61
CALL
DELISTED
Arena Pharmaceuticals Inc
ARNA
$2.07M 0.31%
22,300
-126,400
-85% -$8.33M
MDGL icon
62
Madrigal Pharmaceuticals
MDGL
$10.8B
$2.01M 0.3%
23,700
– –
CLNN icon
63
Clene
CLNN
$64M
$2.01M 0.3%
24,466
– –
TGTX icon
64
TG Therapeutics
TGTX
$7.96B
$1.91M 0.29%
+100,739
New +$2.62M
SVRA icon
65
Savara
SVRA
$1.12B
$1.91M 0.28%
1,539,691
– –
FOLD
66
DELISTED
Amicus Therapeutics
FOLD
$1.9M 0.28%
164,174
-250,000
-60% -$2.79M
TARA icon
67
Protara Therapeutics
TARA
$220M
$1.89M 0.28%
279,256
-200,739
-42% -$1.38M
AUPH icon
68
Aurinia Pharmaceuticals
AUPH
$1.91B
$1.88M 0.28%
+82,335
New +$1.95M
TGTX icon
69
PUT
TG Therapeutics
TGTX
$7.96B
$1.87M 0.28%
98,600
– –
CMMB
70
Chemomab Therapeutics
CMMB
$11.4M
$1.83M 0.27%
66,316
-5,000
-7% -$177K
ODT
71
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$1.81M 0.27%
1,340,631
-500,000
-27% -$1.18M
LYRA
72
DELISTED
LYRA THERAPEUTICS INC
LYRA
$1.72M 0.26%
7,891
-178
-2% -$57.2K
NUVB icon
73
Nuvation Bio
NUVB
$2.2B
$1.7M 0.25%
+200,000
New +$1.84M
BBIO icon
74
CALL
BridgeBio Pharma
BBIO
$15.7B
$1.67M 0.25%
+100,000
New +$4.23M
MRUS
75
DELISTED
Merus
MRUS
$1.62M 0.24%
50,907
– –
1 2
3
4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2021 Portfolio in Review

As of Q4 2021, Ikarian Capital held 248 positions worth $671M, down 53% from $1.42B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Ikarian Capital withdrew a net $596M in Q4 2021, closing 62 positions and reducing 53 holdings. Its most notable exit was Apellis Pharmaceuticals, an estimated $13.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, up from 30% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, Ikarian Capital opened a new position in Kezar Life Sciences worth $17.1M.

  • Ikarian Capital's largest Q4 2021 buy was Kezar Life Sciences: 102,092 shares worth $17.1M.
  • Ikarian Capital added most to Zentalis Pharmaceuticals in Q4 2021, an estimated $7.64M increase.
  • Ikarian Capital's biggest Q4 2021 reduction was Xenon Pharmaceuticals, cutting an estimated $5.93M.
  • Ikarian Capital fully exited Apellis Pharmaceuticals in Q4 2021, selling an estimated $13.7M.
  • Ikarian Capital's ten largest holdings make up 42% of its $671M portfolio in Q4 2021.
  • Ikarian Capital opened 39 new positions and closed 62 in Q4 2021.
  • Ikarian Capital's portfolio value fell 53% quarter-over-quarter to $671M.

Based on Ikarian Capital's 13F filing for Q4 2021, filed 14 Feb 2022.